ImmuCell Initiates Investigational Use of Re-Tain for Subclinical Mastitis in Dairy Cows
Key Insights
ImmuCell Corporation (search) has begun investigational product use of Re-Tain (search)®, a novel treatment for subclinical mastitis (search) in dairy cows that offers an alternative to traditional antibiotics without milk discard requirements.
The controlled launch will allow ImmuCell to test market acceptance and collect performance data while awaiting full FDA approval, which is currently pending final regulatory review and facility inspections.
Re-Tain (search)® represents a significant advancement in dairy cattle health management, addressing the critical need for antibiotic alternatives in the dairy industry while maintaining productivity.
ImmuCell Corporation (search) (Nasdaq: ICCC) announced on April 2, 2025, that it has initiated investigational product use of Re-Tain (search)®, its novel treatment for subclinical mastitis (search) in dairy cows. This strategic move allows the company to begin collecting real-world performance data while the product awaits final regulatory approval.
The Portland, Maine-based animal health company will conduct a controlled launch to assess market acceptance of Re-Tain (search)®, which offers a significant advantage over traditional antibiotics by eliminating FDA-required milk discard or pre-slaughter withdrawal periods. This initiative also serves a practical purpose of utilizing available inventory before shelf-life expiration, though the company does not anticipate generating substantial revenue or profit during this phase.
"This investigational strategy allows us to collect product performance data on Re-Tain (search)® while full NADA approval is pending the final stages of review," explained Michael F. Brigham, President and CEO of ImmuCell. "After all these years in drug development, we can soon begin to see how this product performs on farms."
Regulatory Status and Path to Approval
ImmuCell submitted its Non-Administrative New Animal Drug Application (NADA) in early January 2025, which included its fourth submission of the Chemistry, Manufacturing, and Controls (CMC) Technical Section along with minor technical sections covering All Other Information and Product Labeling. According to the company, the primary hurdle remaining for full approval is clearing inspectional observations at the facilities of its contract manufacturer.
The development of Re-Tain (search)® represents years of research and development investment for ImmuCell, which has positioned the product as an innovative solution for a common and costly dairy cattle health issue.
Addressing an Unmet Need in Dairy Production
Subclinical mastitis (search) represents a significant economic burden for dairy producers worldwide. Unlike clinical mastitis, which presents visible symptoms, subclinical cases show no obvious signs but still reduce milk production and quality while potentially progressing to more severe infections.
Current treatment options typically involve antibiotics that require milk to be discarded during treatment and withdrawal periods, creating substantial economic losses for producers. Re-Tain (search)® aims to address this challenge by providing an effective treatment without these restrictions.
Market Implications
The dairy industry has been seeking alternatives to traditional antibiotics amid growing concerns about antimicrobial resistance and consumer demand for reduced antibiotic use in food production. Re-Tain (search)® could potentially fulfill this market need while improving dairy farm economics.
ImmuCell has established itself in the animal health sector with its First Defense (search)® product line, which provides immediate immunity to newborn dairy and beef calves. The addition of Re-Tain (search)® would expand the company's portfolio in the dairy cattle health management space.
Looking Forward
While the investigational use phase is not expected to generate significant immediate financial returns, it represents a critical step in Re-Tain (search)®'s commercialization journey. The data collected during this period will likely inform the company's full-scale launch strategy once regulatory approval is secured.
Industry observers will be watching closely to see how dairy producers respond to the product and whether it delivers on its promise of effective mastitis treatment without production disruptions. Success in this area could potentially reshape treatment protocols for subclinical mastitis (search) management across the dairy industry.
For ImmuCell, the progression of Re-Tain (search)® toward full market approval represents the culmination of a long-term development effort and a potential turning point for the company's growth trajectory in the animal health sector.